177 related articles for article (PubMed ID: 17300926)
21. Cartilage degradation independent of MMP/aggrecanases.
Sugimoto K; Iizawa T; Harada H; Yamada K; Katsumata M; Takahashi M
Osteoarthritis Cartilage; 2004 Dec; 12(12):1006-14. PubMed ID: 15564068
[TBL] [Abstract][Full Text] [Related]
22. Activation of cartilage matrix metalloproteinases by activated protein C.
Jackson MT; Smith MM; Smith SM; Jackson CJ; Xue M; Little CB
Arthritis Rheum; 2009 Mar; 60(3):780-91. PubMed ID: 19248107
[TBL] [Abstract][Full Text] [Related]
23. Proteoglycan synthesis by fibroblast cultures initiated from regions of adult bovine tendon subjected to different mechanical forces.
Vogel KG; Keller EJ; Lenhoff RJ; Campbell K; Koob TJ
Eur J Cell Biol; 1986 Jun; 41(1):102-12. PubMed ID: 3792332
[TBL] [Abstract][Full Text] [Related]
24. [Cartilage degradation in rheumatoid arthritis].
Ishiguro N
Clin Calcium; 2009 Mar; 19(3):347-54. PubMed ID: 19252244
[TBL] [Abstract][Full Text] [Related]
25. Aggrecan protects cartilage collagen from proteolytic cleavage.
Pratta MA; Yao W; Decicco C; Tortorella MD; Liu RQ; Copeland RA; Magolda R; Newton RC; Trzaskos JM; Arner EC
J Biol Chem; 2003 Nov; 278(46):45539-45. PubMed ID: 12890681
[TBL] [Abstract][Full Text] [Related]
26. Molecular parameters indicating adaptation to mechanical stress in fibrous connective tissue.
Milz S; Benjamin M; Putz R
Adv Anat Embryol Cell Biol; 2005; 178():1-71. PubMed ID: 16080262
[TBL] [Abstract][Full Text] [Related]
27. Chronic tendon pathology: molecular basis and therapeutic implications.
Riley G
Expert Rev Mol Med; 2005 Mar; 7(5):1-25. PubMed ID: 15796783
[TBL] [Abstract][Full Text] [Related]
28. Aggrecan in bovine tendon.
Vogel KG; Sandy JD; Pogány G; Robbins JR
Matrix Biol; 1994 Mar; 14(2):171-9. PubMed ID: 7520336
[TBL] [Abstract][Full Text] [Related]
29. Assays of proteoglycan and collagen degradation in cultures of rabbit cartilage explants.
Lesur C; Sabatini M
Methods Mol Med; 2004; 100():219-36. PubMed ID: 15280598
[TBL] [Abstract][Full Text] [Related]
30. Neoepitope antibodies against MMP-cleaved and aggrecanase-cleaved aggrecan.
Fosang AJ; Last K; Stanton H; Golub SB; Little CB; Brown L; Jackson DC
Methods Mol Biol; 2010; 622():312-47. PubMed ID: 20135291
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitors.
Bottomley KM; Borkakoti N; Bradshaw D; Brown PA; Broadhurst MJ; Budd JM; Elliott L; Eyers P; Hallam TJ; Handa BK; Hill CH; James M; Lahm HW; Lawton G; Merritt JE; Nixon JS; Röthlisberger U; Whittle A; Johnson WH
Biochem J; 1997 Apr; 323 ( Pt 2)(Pt 2):483-8. PubMed ID: 9163342
[TBL] [Abstract][Full Text] [Related]
32. Development of a high-throughput screening assay for inhibitors of aggrecan cleavage using luminescent oxygen channeling (AlphaScreen ).
Peppard J; Glickman F; He Y; Hu SI; Doughty J; Goldberg R
J Biomol Screen; 2003 Apr; 8(2):149-56. PubMed ID: 12844435
[TBL] [Abstract][Full Text] [Related]
33. Aggrecanolysis and in vitro matrix degradation in the immature bovine meniscus: mechanisms and functional implications.
Wilson CG; Vanderploeg EJ; Zuo F; Sandy JD; Levenston ME
Arthritis Res Ther; 2009; 11(6):R173. PubMed ID: 19919704
[TBL] [Abstract][Full Text] [Related]
34. Immortalized mouse articular cartilage cell lines retain chondrocyte phenotype and respond to both anabolic factor BMP-2 and pro-inflammatory factor IL-1.
Majumdar MK; Chockalingam PS; Bhat RA; Sheldon R; Keohan C; Blanchet T; Glasson S; Morris EA
J Cell Physiol; 2008 Apr; 215(1):68-76. PubMed ID: 17960567
[TBL] [Abstract][Full Text] [Related]
35. Structure of the human tibialis posterior tendon.
Petersen W; Hohmann G; Pufe T; Tsokos M; Zantop T; Paulsen F; Tillmann B
Arch Orthop Trauma Surg; 2004 May; 124(4):237-42. PubMed ID: 12695917
[TBL] [Abstract][Full Text] [Related]
36. Tendon proteoglycans: biochemistry and function.
Yoon JH; Halper J
J Musculoskelet Neuronal Interact; 2005 Mar; 5(1):22-34. PubMed ID: 15788868
[TBL] [Abstract][Full Text] [Related]
37. Selective and non-selective metalloproteinase inhibitors reduce IL-1-induced cartilage degradation and loss of mechanical properties.
Wilson CG; Palmer AW; Zuo F; Eugui E; Wilson S; Mackenzie R; Sandy JD; Levenston ME
Matrix Biol; 2007 May; 26(4):259-68. PubMed ID: 17174540
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms involved in cartilage proteoglycan catabolism.
Caterson B; Flannery CR; Hughes CE; Little CB
Matrix Biol; 2000 Aug; 19(4):333-44. PubMed ID: 10963994
[TBL] [Abstract][Full Text] [Related]
39. MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays.
Sumer EU; Sondergaard BC; Rousseau JC; Delmas PD; Fosang AJ; Karsdal MA; Christiansen C; Qvist P
Osteoarthritis Cartilage; 2007 Feb; 15(2):212-21. PubMed ID: 16997584
[TBL] [Abstract][Full Text] [Related]
40. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity.
Karsdal MA; Madsen SH; Christiansen C; Henriksen K; Fosang AJ; Sondergaard BC
Arthritis Res Ther; 2008; 10(3):R63. PubMed ID: 18513402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
